Printing And Publishing Tenders

Oh-Biologika-2023-12 - Insulin, Normal (Human) (Dosage Form: Cylinder Ampoules)

Saso - Security Assessment and System Optimisation

Conclusion of Non-Exclusive Drug Discount Agreements According to § 130A Para. 8 Sgb V by Means of a So-Called Open House Model for the Active Ingredient Bimatoprost (Atc Code According to Who: S01ee03)

Conclusion of Non-Exclusive Discount Agreements According to § 130A Paragraph 8 Sgb V (Open House Model)

Conclusion of Non-Exclusive Discount Agreements According to § 130A Abs. 8 Sgb V for the Active Ingredient Dapagliflozin

Contract for the Distribution Partnership for the Phoenix Product Group

Completion of Non-exclusive Drug Discounts According to Section 130a (8) Sgb V by Means of a So-called Open-house Model to the Active Ingredient Bimatoprost (atc Code According to Who: S01e03)

Open Framework Agreement on Drug Discounts in Accordance with § 130A Paragraph 8 Sgb V with the Option to Join at any Time, So-Called Approval Model 2023-05

Completion of a Non-Excl. Discount Agreement According to § 130C Paragraph 1 Sgb V for Sofosbuvir, Velpatasvir, Voxilaprevir, Atc Code: J05ap56 for the Period from 06/01/2023 to 05/31/2025

Completion of a Non-Excl. Discount Agreement According to § 130A Paragraph 8 Sgb V for Alirocumab, Atc Code: C10ax14 for the Period from 06/01/2023 to 05/31/2025